IP Library › Granted Patent US 10,610,580
Granted Patent B2
US 10,610,580 · App. 16/278,562 · Granted Apr 7, 2020

Attenuated

Inventors: Camille Locht (Brussels, BE); Nathalie Mielcarek (Blandain, BE); Anne-Sophie Debrie (La Madeleine, FR); Dominique Raze (Gruson, FR); Julie Bertout (Pont-à-Marcq, FR)
A61K39/099A61K2039/522A61K2039/523A61K2039/543
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,610,580
App. No.
16/278,562
Granted
Apr 7, 2020
Kind
B2
Abstract

A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.

Claims (8)

1. A method of making single doses of an immunogenic composition comprising a pharmaceutically acceptable carrier and a dose of a live attenuated Bordetella pertussis strain which is able to colonize a subject when administered to the subject, the method comprising the steps of: providing the live attenuated Bordetella strain, wherein the strain comprises at least a mutated pertussis toxin (ptx) gene, a deleted or mutated dermonecrotic toxin (dnt) gene, and a heterologous ampG gene replacing the Bordetella ampG gene; mixing the live attenuated Bordetella strain with a pharmaceutically acceptable carrier to yield an immunogenic composition mixture; and separating the immunogenic composition mixture into single doses.

2. The method of claim 1 , wherein the replacement of the Bordetella ampG gene with the heterologous ampG gene causes the Bordetella strain to express less than 5% of the tracheal cytotoxin (TCT) activity as that expressed by a Bordetella strain which does not have its native Bordetella ampG gene replaced with the heterologous ampG gene.

3. The method of claim 1 , wherein the live attenuated Bordetella strain comprises a heterologous expression platform which carries a heterologous antigen.

4. The method of claim 3 , wherein the heterologous antigen is one expressed by a respiratory pathogen selected from the group consisting of: Neisseria, Pneumophila, Yersinia, Pseudomonas, Mycobacteria , and Influenza.

5. The method of claim 1 , wherein the immunogenic composition is formulated as a powder.

6. The method of claim 1 , wherein the immunogenic composition is formulated as a liquid.

7. The method of claim 1 , wherein the immunogenic composition is formulated as a gel.

8. The method of claim 1 , wherein the live attenuated Bordetella strain is a live attenuated Bordetella pertussis strain.

Assignments (1)
SECURITY INTEREST Recorded Sep 23, 2024
From: ILIAD BIOTECHNOLOGIES, LLC
To: AVENUE CAPITAL MANAGEMENT II, L.P.
Reel/Frame 068668/0854 →